This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carlo-Stella, C. Articles by Gianni, L. Search for Related Content PubMed PubMed Citation Articles by Carlo-Stella, C. Articles by Gianni, L.

Targeting TRAIL Agonistic Receptors for Cancer Therapy

Authors' Affiliations: ¹ "Cristina Gandini" Medical Oncology Unit and ² Medical Oncology 1, Istituto Nazionale Tumori, and ³ Medical Oncology, University of Milan, Milan, Italy

Requests for reprints: Alessandro M. Gianni, "Cristina Gandini" Medical Oncology Unit, Istituto Nazionale Tumori, Via Venezian, 1-20133 Milan, Italy. Phone: 39-2-2390-2532; Fax: 39-2-2390-3461; E-mail: Alessandro.Gianni{at}unimi.it.

Based on preclinical studies demonstrating that tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) exerts a potent and cancer cell–specific proapoptotic activity, recombinant TRAIL as well as agonistic anti–TRAIL-R1 and anti–TRAIL-R2 antibodies recently entered clinical trials. Additionally, gene therapy approaches using TRAIL-encoding adenovirus (Ad-TRAIL) are currently being developed to overcome the limitations inherent to TRAIL receptor targeting, i.e., pharmacokinetic of soluble TRAIL, pattern of receptor expression, and tumor cell resistance. To optimize gene therapy approaches, CD34⁺ cells transduced with Ad-TRAIL (CD34-TRAIL⁺) have been investigated as cellular vehicles for TRAIL delivery. Transduced cells exhibit a potent tumor killing activity on a variety of tumor cell types both in vitro and in vivo and are also cytotoxic against tumor cells resistant to soluble TRAIL. Studies in tumor-bearing nonobese diabetic/severe combined immunodeficient mice suggest that the antitumor effect of CD34-TRAIL⁺ cells is mediated by both direct tumor cell killing due to apoptosis and indirect tumor cell killing due to vascular-disrupting mechanisms. The clinical translation of cell and gene therapy approaches represent a challenging strategy that might achieve systemic tumor targeting and increased intratumor delivery of the therapeutic agent.

This article has been cited by other articles:

				B. Sadikovic, M. Yoshimoto, S. Chilton-MacNeill, P. Thorner, J. A. Squire, and M. Zielenska Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling Hum. Mol. Genet., June 1, 2009; 18(11): 1962 - 1975. [Abstract] [Full Text] [PDF]

				B. Ren, K. Song, S. Parangi, T. Jin, M. Ye, R. Humphreys, M. Duquette, X. Zhang, N. Benhaga, J. Lawler, et al. A Double Hit to Kill Tumor and Endothelial Cells by TRAIL and Antiangiogenic 3TSR Cancer Res., May 1, 2009; 69(9): 3856 - 3865. [Abstract] [Full Text] [PDF]

				W. W. Ma and A. A. Adjei Novel Agents on the Horizon for Cancer Therapy CA Cancer J Clin, March 1, 2009; 59(2): 111 - 137. [Abstract] [Full Text] [PDF]

				C. Wang, T. Chen, N. Zhang, M. Yang, B. Li, X. Lu, X. Cao, and C. Ling Melittin, a Major Component of Bee Venom, Sensitizes Human Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Activating CaMKII-TAK1-JNK/p38 and Inhibiting I{kappa}B{alpha} Kinase-NF{kappa}B J. Biol. Chem., February 6, 2009; 284(6): 3804 - 3813. [Abstract] [Full Text] [PDF]

				T Sumi, W Ishida, K Okumura, H Yagita, and A Fukushima Activation of tumour-necrosis factor-related apoptosis-inducing ligand receptor enhances the severity of murine allergic conjunctivitis Br. J. Ophthalmol., January 1, 2009; 93(1): 110 - 115. [Abstract] [Full Text] [PDF]

				L. M. Knowles, C. Yang, A. Osterman, and J. W. Smith Inhibition of Fatty-acid Synthase Induces Caspase-8-mediated Tumor Cell Apoptosis by Up-regulating DDIT4 J. Biol. Chem., November 14, 2008; 283(46): 31378 - 31384. [Abstract] [Full Text] [PDF]